Corrigendum to: Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population
J Infect Dis. 2020 Mar 16;221(7):1204.
doi: 10.1093/infdis/jiz599.
1 Department of Bacterial and Parasitic Diseases, US Army Medical Directorate of the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
2 The Henry M. Jackson Foundation for the Advancement of Military Medicine.
3 Experimental Therapeutics Branch.
4 General Dynamics Information Technology, Silver Spring.
5 Clinical Trials Center.
6 Food and Drug Administration, Boston, Massachusetts.
7 Davita Medical Group, Colorado Springs, Colorado.
8 Division of Infectious Disease, SUNY Upstate Medical University, Syracuse, New York.
9 Licensing and Early Development-Oncology, Genentech, South San Francisco, California.
10 Malaria Vaccine Branch.
11 Clinical Operations, Government and Public Health Solutions, ICON, Hinckley, Ohio.
12 Vaccines/Therapeutics Division, Defense Threat Reduction Agency, Fort Belvoir, Virginia.
13 Clinical Pharamacology Division, Uniformed Services University of the Health Sciences.
14 U. S. Army Medical Materiel Development Activity, Fort Detrick, Maryland.
15 Center for Enabling Capabilities.
16 Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences.
17 Bacterial Diseases Branch, Walter Reed Army Institute of Research.